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Janus dendrimers are amphiphilic macromolecules that have shown promising potential in the 
biomedical field. Due to their unique structure and properties, these branched block copolymers 
have the ability to self-assemble into bioinspired spherical nanoaggregates. Because they possess 
a hydrophobic and hydrophilic moiety, these aggregates show potential as drug delivery systems 
that can transport both hydrophobic and hydrophilic drugs. However, many of the proposed 
dendrimer systems suffer from certain weaknesses that hinder their practical usage as clinical 
treatment options. Some of these shortcomings include specificity, solubility, size, surface charge, 
and mechanical properties. To combat these problems, we synthesized and characterized a library 
of PAMAM-fatty acid (PAMAM-FA) hybrid Janus dendrimers that offer solutions to the issues 
that traditional dendrimers have. These hybrids have a cationic NH3
+, an anionic COO-, and a 
neutral OH surface functionality on the PAMAM moiety, and they have been covalently bonded 
to fatty acids via click chemistry. These dendrimers show potential in biomedical applications to 
enhance specificity and to add biological markers to the surface of the PAMAM branches. The 
nanoparticles in aqueous solution were characterized using microscopy (TEM) and light scattering 
(DLS), and diameters ranged from 40 to 100 nm. Zeta-potential values ranged from -17.9 mV to 
+58.7 mV in accordance with the respective surface functionality. TEM images revealed spherical 
morphologies and showed critical aggregate concentrations (CAC) that ranged from 0.92 to 1.9 
µmol/L. The results of our study exhibit strong evidence for the potential use of these hybrids in 
biomedical applications and clinical settings.  
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BACKGROUND AND INTRODUCTION 
Researchers have been searching for cancer treatments for decades due to the severity and 
prevalence of the disease. Cancer cells divide uncontrollably, they metastasize to other parts of the 
body, and they harm surrounding healthy cells by consuming available nutrients. Doctors have 
been unable to find a singular cure for all cancer types due to the vast complexity and variability 
among them. In addition, it is difficult to target cancer cells specifically. Chemotherapy and 
radiation kill cancer cells, but they also kill the surrounding healthy cells. These current methods 
and medications have advanced, but they still have their shortcomings such as drug loading 
efficiencies, drug releasing efficiencies, biocompatibility, etc. Due to the lack of selectivity, the 
many side-effects including hair loss, fatigue, and decreasing immunity often cause additional 
problems for patients. In addition to selectivity issues, cancer drugs are typically hydrophobic, so 
it is difficult to transport them via the bloodstream to the target site due to their insolubility.  
To resolve these problems of specificity, potency, and solubility, scientists have 
investigated potential therapies to target cancer sites and minimize the death of healthy cells. One 
of these therapies include targeted drug delivery using synthetic molecules. Drug delivery systems 
(DDS) have the potential to revolutionize cancer treatments, and they have other biomedical 
applications, such as antibiotic therapy1 and gene transfection2. For drug delivery, these vehicles 
behave as transports to carry drugs to a specific location to be released at a specific time. Scientists 
have the ability to manage the location specificity via the surface modifications on the DDS. They 
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can also control the release time and rate through the stability and degradation of the vehicle. These 
controllable aspects of drug delivery systems drove research scientists to develop different types 
of DDSs and continue to optimize them.  
Researchers have been tirelessly searching for candidates for targeted drug delivery, and 
there are many vehicles that have been put forth as potential solutions. The ideal DDS is an 
amphiphilic nanoparticle that can self-assemble into a stable bilayer vesicle to deliver hydrophilic 
and hydrophobic drugs to a specific target site. Many of the current vehicles that have been 
synthesized have benefits, but they also have disadvantages. Liposomes are made up of lipids that 
can form a bilayer with the potential to house hydrophobic and hydrophilic drugs. However, the 
liposome’s lipids do not spontaneously self-assemble. They must be sonicated to take shape, but 
this method can destroy the phospholipid rendering it an ineffective strategy.3 Polymeric micelles 
are also a well-studied potential vehicle. They are amphiphilic, but rather than a bilayer, they form 
a single layer with the hydrophilic heads on the exterior. Although these are easy to prepare, they 
have a substantial risk of degrading after they have been administered.3 The early degradation 
would cause the drugs to be unleashed too early and kill the healthy cells rather than reaching the 
target site. 
Another popular type of DDS is a dendrimer. In recent years, dendrimers have become one 
of the primary topics of supramolecular chemistry due to their numerous promising medical 
applications to solve the previously stated issues. Dendrimers are symmetrical, tree-like 
macromolecules that can be synthesized in a variety of ways.4 Some of their benefits include their 
tunability and controlled synthesis.5 Traditional dendrimers consist of a central core that allows 
for a repeating monomer to branch off and continue to repeat in a systematic way.5 Each additional 
monomer on the branches constitutes the next “generation” of that dendrimer. The branches end 
3 
with an exterior functional group that can be modified to reduce toxicity or attach fluorescent 
moieties.5  
  
Figure 1.: Traditional G2 PAMAM dendrimer6 
 
Dendrimers have been synthesized with a variety of monomers to form various types of 
macromolecules. One well-studied type is a polyamidoamine (PAMAM) dendrimer which has 
been studied since it was introduced by Donald A. Tomalia in 1985.7 Figure 1 shows the structure 
of a traditional PAMAM dendrimer. It grows symmetrically from the center with repeating methyl 
acrylate and ethylenediamine segments to form a globular, symmetric macromolecule.  
4 
Dendrimers show significant potential for future biomedical applications, but they still 
have some disadvantages. Some of these include rapid systemic clearance, toxicology issues, 
solubility, inefficient drug loading, and uncontrolled drug release.8 To combat these problems, a 
new class of dendrimers emerged called Janus dendrimers (JDs).  
JDs are unique because they lack the symmetric structure of a traditional dendrimer. In 
contrast, they possess two different dendrons, typically one hydrophilic and hydrophobic dendron, 
that are connected at the central core. Due to their amphiphilic character, these molecules have the 
ability to self-assemble into supramolecular nanoaggregates with a variety of structures, including 
tubes, micelles, and bilayer vesicles.5,9  
These molecules have been shown to self-assemble into stable nanoaggregates by several 
researchers. For example, Percec et. al reported that their bilayer vesicles, or dendrimersomes, had 
much better mechanical properties than both liposomes and polymersomes.9 Additionally, Peterca 
et. al reported that their dendrimersomes had mechanical properties that are equivalent to vehicles 
that are already being used in drug delivery to treat cancer patients.10  
Their ability to self-assemble into stable aggregates combined with JDs’ highly 
controllable structure allows them to resolve some of the previously stated issues that are 
associated with traditional dendrimers. Not only are chemists able to manipulate the outer 
functional groups to enhance selectivity, but they can also manipulate the building blocks of the 
dendrons to combat cytotoxicity. The self-assembled aggregates have the potential to encapsulate 
both hydrophobic and hydrophilic drugs, therefore potentially solving the solubility issue. Their 
stronger mechanical properties could resolve the drug loading and release problems, as well. Due 
to their amphiphilicity, JDs have the potential to offer solutions to many of the problems that 
traditional dendrimers could not overcome. 
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Interestingly, there are different types of JDs that have been suggested by various 
researchers. Previously, we investigated linear dendritic block copolymers (LDBCs). These 
macromolecules possess a branched hydrophilic PAMAM moiety and a linear hydrophobic 
moiety. These molecules were studied by manipulating the weight ratio of hydrophilic to 
hydrophobic moieties and observing changes in morphology and size. The LDBCs showed 
promise as they self-assembled to form bilayer vesicles, which is the ideal shape for biomedical 
applications. In addition, the ideal diameter, 50 to 65 nm, was achieved in this study. However, 
surface functionalization was not discussed.11 To further expand on this area of study, our goal is 
to be able to establish a synthetic route, as well as develop JDs based on PAMAM and FAs as 
viable candidates, that will capitalize on the current abilities we have established for JDs and 
minimize the current problems we see in polymeric drug delivery systems. 
SCIENTIFIC RATIONALE 
There are many different types of polymers and dendrimers in literature that have been 
used to synthesize JDs. One of the more popular choices is polyamidoamine (PAMAM). We chose 
PAMAM because it is well studied in literature and still widely used in DDS research. Because 
we are synthesizing JDs, only about a quarter of a traditional PAMAM dendrimer is being used to 
create the hydrophilic moiety of our hybrids. It is a highly branched structure, making it more ideal 
for drug loading, and it has a highly controlled and systematic synthesis. It also can be terminally 
functionalized with various end groups which allows for further potential biomedical applications 
and decreased toxicity.12 In addition, PAMAM is made up of repeating methyl acrylate and 
ethylenediamine segments that form amide bonds. These bonds resemble the structure of 
biological proteins that also possess repeating amide bonds.2,12 These polypeptide-like bonds cause 
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this highly branched structure to take on some properties of proteins, sometimes being referred to 
as “artificial proteins,” and they have been found to have low mammalian toxicity.2   
While PAMAM is used for the hydrophilic portion, the hydrophobic portion is made up of 
fatty acids (Figure 2). These molecules are a more familiar term and are a well understood in 
biology and medicine. Biologists have known for a long time about their roles in cell membranes 
and energy storage in humans.13 Because they are native to the human body, they are 
biocompatible and biodegradable, making them a logical candidate to use in the synthesis of 
delivery vehicles.14  Like PAMAM, there are also several studies that have been recorded in the 
literature about their influence in drug delivery.4,14,15 For example, Silvia Hernández-Ainsa et. al 
ionically functionalized their PAMAM G2 dendrimers with fatty acids of varying sizes to 
determine the effects on the self-assembling properties of their vehicles.15 Our study also employed 
the use of fatty acids to observe their effects on the self-assembling properties, however, our fatty 
acids are covalently bonded rather than ionically bonded. Fatty acids can be attached covalently 
via esterification to 2,2-bis(hydroxymethyl) propionic acid (bis-MPA) based dendrimers.4 A bis-
MPA based dendrimer, which is a well-studied type of delivery system, was employed in our 
vehicle because using a covalent bond yields a more stable molecule that does not rely on the 
number of positive and negative ions.4,16 Additionally, bis-MPA dendrimers are polyesters making 
them biodegradable and biocompatible, and their terminal alcohol groups allow it to be protected, 
deprotected, and esterified with fatty acids.16 Another advantage of the bis-MPA core is the ability 
to manipulate the number of terminal alcohol groups, similar to manipulating the number of 
PAMAM terminal groups. With this high level of control, we can do further studies on the impact 




Figure 2. Fatty acid portion of the hybrid 
 
Herein, we introduce the novel PAMAM-Bis-MPA-4-Fatty Acid hybrid dendrimer with a 
PAMAM-G3 moiety and a Bis-MPA based moiety esterified with 4 fatty acid chains (Figure 3). 
As previously stated, PAMAM was a logical choice for the hydrophilic portion due to the extensive 
research that has already been conducted by numerous researchers.8,9,10 For this work, we chose to 
use generation 3 (G3) for our hybrids. Studies have shown that larger generations of PAMAM 
suffer from steric crowding due to excessive branching,12 while smaller generations are too flexible 
leading to cargo leaking.17  
This macromolecule has been successfully synthesized with three different end groups. 
These include a carboxylic acid which becomes anionic in PBS buffer (COO-) at pH = 7.4, a neutral 
alcohol (OH), and a cationic amine (NH3
+) in Milli Q water at pH = 7.0. For the lipophilic portion, 
we introduced the fatty acid side chains on an azide-bis-MPA-4-OH dendron. They have the 
potential to increase the mechanical properties and, therefore, the strength and stability of the 
nanocarrier due to stronger hydrophobic interactions. The two segments were joined via click 
 
8 
chemistry. Upon deprotection, the dendrimers become amphiphilic and have the ability to self-
assemble into nanoparticles. 
 
Figure 3. The three PAMAM-FA hybrids 
9 
The design and synthesis of these dendrimers are unique and novel in that they can be 
modified with a variety of end groups. The exterior groups on the PAMAM moiety include a 
carboxylate, alcohol, and an amine. Each of these groups has a protecting group that can be 
removed in the final step of the synthesis. These protecting groups are tert-butyl ester (TBE), 
tetrahydropyran (THP), and tert-butoxycarbonyl (BOC). The TBE end group protects the 
carboxylic acid, THP protects the neutral alcohol, and BOC protects the amine. These end groups 
have exhibited different benefits in various studies. For example, cationic terminal amines have 
shown increased uptake,18 anionic nanoparticles have shown higher circulation time in the 
bloodstream,19 and neutral nanoparticles have been reported as a successful delivery system 
without appreciable toxicity.20 
The three different end groups on our vehicles also provide another benefit for potential 
use. The terminal carboxylate, amine, and alcohol can be the starting materials to add a variety of 
biochemical molecules to the exterior groups on the PAMAM portion of the vehicle. This high 
level of specificity with respect to the outer groups is particularly valuable for cancer treatments. 
Different types of cancerous cells have different properties, which leads to the difficulty in 
synthesizing a single cure. However, our JDs have the potential to be a starting molecule from 
which more specific vehicles could be synthesized. In other words, a JD’s hydrophilic terminal 
end groups could be modified with biochemical markers to find specific types of cancer cells, thus 
further increasing the specificity of the vehicles.  
Overall, our new PAMAM-fatty acid hybrid JD shows promising potential in combating 
many of the numerous issues that have hindered the advancement of specific cancer treatments 
including toxicity to healthy cells, potency, solubility, and stability.
10 
 





Our PAMAM-fatty acid hybrid contains two dendritic moieties joined together via click 
chemistry. PAMAM makes up the hydrophilic portion, and the fatty acids are hydrophobic (Figure 
4). PAMAM is synthesized with alternating Michael additions and amidations using methyl 
acrylate and ethylenediamine to create a branched polymer. Because of the stepwise repetition, 
PAMAM can be synthesized to form varying sizes with different amounts of branching.  
 





PAMAM is also ideal for terminal functionalization. We have successfully functionalized 
the terminal ends with three different groups (Figure 5). The functionalization of the PAMAM 
surface is important to the toxicity of the vehicle.2,12 The repeating amide segments mimic the 
makeup of biological molecules,2 however, exposed cationic amine groups are toxic to human 
cells.21 The large positive charge rips the anionic cell membrane of human cells apart, therefore 
it is harmful to healthy cells.21 However, it is beneficial to have a small overall positive charge to 
encourage interaction between the DDS and cells.  
 
 
Figure 5. The three PAMAM moieties with TBE, BOC, and THP protection groups  
 
The various end groups also allow the potential for other biochemical groups to be 
covalently bonded to the ends of the PAMAM moiety. This could lead to advancements in 
increasing specificity. For example, some forms of cancer overexpress biotin receptors on the cell 
surface.22 By attaching biotin to the ends of PAMAM, the DDSs will be more likely to dock with 
the cancer cells and unload the drugs at that specific location.22 The different biomarkers can be 
PAMAM-TBE PAMAM-BOC PAMAM-THP 
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chemically attached with a variety of reactions including acylation, Michael addition, and 
amidation.23 
The PAMAM dendron was synthesized using the divergent method. This method uses the 
core as the starting point and grows the branches from this central molecule.2 The core functional 
group for PAMAM is propargyl amine. The first half-generation of PAMAM is formed via a 
Michael addition with the core and methyl acrylate. This step is followed by a nucleophilic 
amidation with ethylenediamine to yield the first full generation. These steps are repeated to grow 
the PAMAM dendron until generation 3 (Scheme S4). The amine-terminated generation 3 dendron 
was treated with di-tert-butyl dicarbonate in methanol to obtain P-PAMAM-G3-BOC with 92% 
yield. PAMAM generation 2.0 was treated with tertbutyl acrylate in methanol to obtain P-
PAMAM-G3-TBE with a 90% yield. PAMAM generation 2.5 was treated with ((tetrahydro-2H-
pyran-2-yl)oxy)methanamine in methanol to obtain P-PAMAM-G3-THP with 81% yield (Figure 
6). 
   TBE - tert-butyl ester               THP – tetrahydropyran              BOC- tert-butoxycarbonyl             
                                                           
Figure 6. End groups on the PAMAM moiety  
FATTY ACIDS 
The lipophilic fatty acid chains were chosen for their well-studied nature in human biology. 
Fatty acids are used in the body to make up cell membranes, store energy, and make up other 
macromolecules in the body. The biocompatibility and biodegradability make fatty acids a good 
choice for creating nontoxic drug vehicles. Additionally, the fatty acid chains are responsible for 
13 
the hydrophobic interactions that are the driving force for the self-assembly of the nanocarriers. 
These are the same forces that create the bilayer of cell membranes in the human body, and 
therefore show promise in increasing the stability and strength of DDSs.  
The fatty acid portion contains an azide-bis-MPA-4 core with fatty acids esterified to the 
four terminal alcohol groups. We chose fatty acids because of their potential enhancement of 
mechanical properties of our DDSs. Fatty acids exhibit strong hydrophobic interactions which 
have the potential to strengthen the stability of the vehicle and prevent early release of the drug. In 
addition, fatty acids are a well-understood bio-molecule in the human body, thus the fatty acid 
moiety is biocompatible.  
The bis-MPA core is composed of polyesters, and it is first synthesized with a substitution 
scheme to substitute an alcohol group with an azide to later perform the click reaction. Next, the 
resulting A-MPA-2-OH is esterified with the bis-MPA monomer, followed by an acetal 
deprotection to yield A-MPA-4-OH. The polymer’s terminal alcohol groups are esterified to form 
the final A-bis-MPA-4-FA hydrophobic moiety (Scheme S2).  
The hydrophobic, fatty acid moiety was also synthesized using the divergent method. The 
core of the lipophilic dendron is an azide group, and the branches are grown using a bMPA 
monomer. Using 1,1'-carbonyldiimidazole (CDI) to activate the carbonyl group and cesium 
fluoride (CsF) as a catalyst, a Malkoch esterification yielded A-bis-MPA-OH-4. The 4 alcohol 
groups were esterified with palmitoyl chloride to afford A-bis-MPA-FA-4 with a 91% yield 
(Scheme S2).  Presence of the azide group was confirmed by the FTIR using stretching vibrations 
at 2102 cm-1 (Figure 7).  
14 
 
Figure 7. FTIR spectra for A-MPA-4-FA (10) 
 
PAMAM-FA 
After synthesizing both half-dendrons separately, they were linked via click chemistry. We 
synthesized the core of the 2 dendrons to have a propargyl amine and an azide to covalently bind 
them together using copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) (Figure 8). The 
reaction was carried out with the hydrophobic dendron in excess to increase product yields. It also 
is easier to separate the final JD from the hydrophobic portion due to the greater difference in 
molar mass. This difference allows for separation of the two molecules via size exclusion 
chromatography, a method that is somewhat different from previous methods described in 
literature. Additionally, this method provided good yields of all three JDs (79-86%). After 
purifying the product, the protecting groups on the terminal ends of the PAMAM moiety, TBE, 
BOC, and THP, are removed using trifluoroacetic acid (TFA). The deprotection yields the final 
Janus dendrimers: FA-PAMAM-NH3




Figure 8. Synthetic route for amphiphilic JDs 
 
1H and 13C NMR spectroscopy were used to monitor the reactions and to confirm the 
intermediate products (Figure S1-S30). Additionally, 1H and 13C NMR and GPC were used to 
characterize the final synthetic ‘click’ products. FA-PAMAM-BOC is used to demonstrate the 
characterization results of the compounds. The center triazole ring that forms during the click 
reaction creates a new peak in the 1H NMR spectrum at 8.06 ppm that corresponds to H-3 (Figure 
S24-S23). Additionally, the 13C NMR spectrum exhibits two new peaks at 144 and 125 ppm that 
correspond to C-1 and C-2, respectively, of the triazole ring to further confirm the completion of 
the click reaction (Figure 9). The protons at the α positions of the triazole ring, H-1, correspond to 
the hydrophilic PAMAM moiety, and their peaks shift downfield from 3.62 to 4.40 ppm relative 
to the starting PAMAM dendron (Figure S23). Similarly, the protons at the α positions of the 
triazole ring, H-4, correspond to the hydrophobic fatty acid moiety, and their peaks shift downfield 
from 3.32 to 4.29 relative to the starting fatty acid dendron (Figure S23). The peaks that correspond 
to PAMAM (2.19-3.69 ppm) and bMPA fatty acid (1.57, 5.15 ppm) remained unchanged, and the 
integrations for each peak accurately reflect both hydrophilic and hydrophobic moieties (Figure 
S23).  
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Figure 9. 13C NMR spectrum for FA-PAMAM-BOC in CDCl3 recorded at 400 MHz 
 
Further characterization of the JDs was done using GPC (Table 1). In particular, GPC was 
used to determine the monodispersity of the final product and confirm that there were no free, 
unreacted dendrons that remained in solution after the CuAAC coupling process. GPC was run 
using protected JDs due to their solubility in THF, and each compound’s results revealed a single 
peak on the GPC chromatogram indicating that there is one macromolecule in solution and no free, 
unreacted dendrons (Fig S31-S33). The shoulders that appear in the GPC data is due to the 
hydrophilic branching of the JDs which interacts with the hydrophobic column and affects its 
elution rate.11 In addition, the retention peak of the starting material does not correspond to the 
shoulder on the final product, thus our data shows that we have no free dendrons that had not 







TABLE 1. Molecular Weight Characterization of JDs by GPC with THF as the elution solvent; 
chromatographs shown in the supporting information figures. 
Sample Mth g mol-1 Mn g mol-1 Mw g mol-1 Ða 
FA-PAMAM-G3-BOC 3785 3625 3801 1.05 
FA-PAMAM-G3-TBE 3096 3118 3289 1.06 
FA-PAMAM-G3-THP 3665 3716 3781 1.02 
aMth, Mn, Mw, Ð denote theoretical molar mass, number average molar mass, weight average molar 
mass and dispersity, respectively. In GPC, the dispersity, Ð, refers to the distribution of the 




SELF-ASSEMBLY AND MORPHOLOGY 
 
TABLE 2. CAC values, the average hydrodynamic diameter of the dendritic aggregates by TEM 







(mV) Number                           Intensity
FA-PAMAM-G3-NH3
+ 1.9 ± 0.2 57.8 ± 16.7 103.7 ± 40.3 0.191 56.1 ± 6.5 
FA-PAMAM-G3-OH 0.92 ± 0.2 41.0 ± 9.0 
53.3 ± 12.4 
308.2 ± 85.1 
0.469 8.5 ± 1.6 
FA-PAMAM-G3-COO- 0.92 ± 0.2 93.1 ± 15.9 102.2 ± 14.1 0.882 -17.9 ± 2.6 
aIn DLS, the dispersity, or PDI, refers to the distribution of the different sizes of the aggregates. It 
is measured as the square of the standard deviation divided by the mean, and the ideal value is 
0.1.24 
 
Self-assembly of the three different JDs was accomplished using the nanoprecipitation 
method.25,26 Water was used for the formation of FA-PAMAM-NH3
+ aggregates, and a PBS buffer 
was used for the FA-PAMAM-COO- and FA-PAMAM-OH aggregates. After the nanoparticles 
assembled, we measured the critical aggregation concentration (CAC) (Table 2, Figure S34-S35). 
CAC values correlate to the concentration that determines if the JDs will remain self-assembled. 
If the concentration is above the CAC, they will form the vehicle. Below this concentration, the 
vehicle will not form. The CAC values are measured by using pyrene as a solvatochromic 
fluorophore. Pyrene is a hydrophobic molecule that exhibits different fluorescent profiles 
depending on if it is in water or in a lipophilic medium. If the JDs self-assemble, then pyrene will 
aggregate in the lipophilic layer of the vehicle, and the appropriate fluorescent profile will be 
detected. As a result, the CAC values can be measured. The CAC values can provide an indication 
of the stability of the nanoparticle. A lower CAC value indicates a more stable vehicle relative to 
a higher CAC. It is critical for the CAC to be relatively low due to the vehicles inevitable dilution 
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when it enters the bloodstream. As shown in Table 2, the CAC ranged from 0.92 to 1.9 µmol/L. 
These values are similar to the CAC values of other vehicles that are potential candidates for 
biomedical applications.27,28  
The CAC values for these macromolecules are all relatively low, but they do vary slightly 
based on the surface charge. Positively charged FA-PAMAM-NH3
+ has the largest CAC value (1.9 
µmol/L), and anionic FA-PAMAM-COO- and FA-PAMAM-OH had the smaller value (0.92 
µmol/L). These results suggest that the anionic and neutral JDs form more stable nanoparticles 
than the cationic JD.  
The corresponding diameters for the different JD aggregates were determined using 
dynamic light scattering (DLS) (Table 2, Figure S31-S33). Here we include the number and 
intensity value. The number diameter represents the diameter of the majority of the aggregates 
formed. The intensity diameter is the average diameter of all the aggregates, but the value favors 
the largest aggregates formed. Our research primarily focuses on the number diameter. Anionic 
JDs have a larger particle size with the number average radii 93.1 nm, intensity average radii 102.2 
nm with 0.882 PDI. For the neutral JD, number average radii 41.0 nm, intensity average DLS data 
gave two distributions, small hydrodynamic diameters (53.3 nm), and larger hydrodynamic 
diameter (308.2 nm) with 0.469 PDI (Figure S33). Cationic JD shows similar particle size to 
neutral JD with number average radii 57.8 nm, intensity average radii 103.7 nm with 0.191 PDI. 
Based on the PDI value, cationic JDs and neutral JDs show a narrow size distribution where PDI 
values range from 0.1 to 0.5, and anionic JDs show a broad distribution with a PDI value greater 
than 0.5. All particle sizes are below 200 nm, which indicates that they have the potential to escape 
physiological barriers such as the enhanced permeability and retention effect. They also have a 
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high potential for prolonged circulation and reduced filtration by the liver and spleen. Therefore, 
these nanoparticles can be developed as drug gene delivery agents and cancer therapy agents.29   
Because DLS data is reliant on the spherical shape of the nanoparticle, it is crucial to use 
microscopic examination to determine the morphology. Cryo-TEM reveals the dendrimers’ 
behavior as predicted in aqueous solutions, and it exhibits the different morphologies of the self-
assembled JD aggregates (Figure 10). All of the images show that the JDs form spherical 
nanoparticles when they self-assemble, thus validating the DLS data. The images of FA-PAMAM-
G3-NH3
+ (Figure 10a) showed spherical aggregates with an average particle size of 55.6 nm. The 
images correlated with the DLS data that reported a single average radius of 57.8 nm. FA-
PAMAM-G3-OH (Figure 10b) formed spherical aggregates that were isolated, which had an 
average particle size of 47.5 nm, and they formed clusters of nanoparticle aggregates. This 
explained why the DLS data showed two average radii of 53.2 nm and 308.2 nm. Because DLS is 
not designed to measure multimodal particle size distributions, the signal of the smaller particle is 
much weaker. Finally, FA-PAMAM-G3-COO- (Figure 10c) assembled into spherical aggregates 
with an average particle size of 104.8 nm. This value corresponds to the average radii of 93.1 nm 
that was measured by DLS. In conclusion, the FA-PAMAM-OH JDs formed more aggregates 
relative to the cationic and anionic JDs which could be due to the neutral surface charge. Unlike 
the charged JDs, the neutral JD does not experience charge separation between the nanoparticles. 
This contributes to the formation of more aggregates with the support of hydrogen bonding 




Figure 10. Cryo-TEM images with utilizing uranyl formate as a contrast agent for (A) FA-
PAMAM-G3-NH3
+, (B) FA-PAMAM-G3-OH and (C) FA-PAMAM-G3-COO-. 
 
The zeta potentials were also studied to determine the surface charge of the aggregates 
formed from the amphiphilic JDs (Table 2). FA-PAMAM-G3-NH3
+ had a surface charge of 56.1 
± 6.5 mV in Milli Q water at pH 7.0. FA-PAMAM-G3-COO- had a surface charge of -17.9 ± 2.6 
mV at pH 7.4 in PBS buffer. Lastly, FA-PAMAM-G3-OH had a charge of 8.5 ± 1.6 mV at pH 7.4 
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in PBS solution. The resulting zeta potential values correspond to the expected values of each JD’s 
respective terminal charge. In literature, particles with surface charges below 15 mV displayed the 
ideal properties such as decreased macrophage uptake,30 higher tumor retention, and longer 
circulation time.31 This indicates that our neutral JDs have a greater potential to exhibit these 
properties, as well. Also, the ideal surface charge depends on factors such as cell type, cellular 
uptake mechanism, and intracellular localization of nanoparticles.18,32 Therefore, the cationic and 
anionic JDs have the potential to be useful for other applications in which a more positive or more 




In this study, we successfully synthesized and characterized cationic, anionic, and neutral 
amphiphilic PAMAM-fatty acid Janus dendrimers. TEM and DLS analysis indicate the size of 
spherical nanoparticles ranging from 40 to 100 nm with zeta-potential values ranging from -17.9 
to +58.7 mV concerning the terminal functional group. Further, these systems exhibited spherical 
aggregates with critical aggregate concentrations ranging from 0.92 to 1.9 µmol/L. Of these three, 
the neutral FA-PAMAM-OH had a low CAC value, and the zeta potential revealed an ideal surface 
charge for future biomedical applications. This study showed that Janus dendrimers with neutral 
surface charges exhibit characteristics that indicate their strong candidacy as potential drug 
delivery systems. Further studies regarding drug loading capacity, pH studies, and cytotoxicity 
still need to be conducted. Additional studies regarding the optimization of the vehicle could also 
be conducted to determine the best hydrophilic to hydrophobic ratio to achieve ideal mechanical 
properties. Finally, studies to investigate a synthetic route for JDs with two surface functionalities 
would be beneficial for manipulating the surface charge. Although there is still work to be done in 
the realm of cancer treatment, our results revealed new insights for progress in drug delivery 






















Scheme S4. Synthesis of hydrophilic dendron 
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Reported below are the full synthetic details for the preparation of monomers, dendrons, 
and amphiphilic Janus dendrimers  
 
2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid (2)  
This procedure was adapted from previously reported procedures.1 To the stirred solution of 3-
hydroxy-2-(hydroxymethyl)-2-methylpropanoic acid (100.06 g, 0.750 mol) in 500 mL of acetone, 
2,2-dimethoxypropane (DMP) (116.47 g, 1.12 mol) and p-toluenesulfonic acid (PTSA) (7.10 g, 
37.2 mmol) were added under room temperature. After the completion of the addition, the reaction 
mixture was stirred 5 h. Then it was filtered through an amberlyst column and the solvent was 
evaporated at room temperature. The residue was recrystallized using CH2Cl2 to give (2) white 
crystals with 92% yield (120.20 g). 1H NMR (500 MHz, CDCl3) δ 4.27 – 4.17 (m, 2H), 3.76 – 
3.66 (m, 2H), 1.55 – 1.39 (m, 6H), 1.23 (d, J = 2.8 Hz, 3H).  
 
(2,2,5-trimethyl-1,3-dioxan-5-yl)methanol (4)  
This procedure was adapted from previously reported procedures.2 To the stirred solution of 2-
(hydroxymethyl)-2-methylpropane-1,3-diol (10.10 g, 84.0 mmol) in 50 mL of acetone, 2,2-
dimethoxypropane (DMP) (13.14 g, 0.126 mol) and PTSA (0.79 g, 0. 4.14 mmol) were added 
under room temperature. After the completion of the addition, the reaction mixture was stirred 4 
h. Then it was filtered through an amberlyst column and the solvent was evaporated, and the 
residue was put under 60 oC and full vacuum for 2 h. Then it was put under vacuum overnight to 
give (4) as a colourless liquid with 96% yield (12.91 g). 1H NMR (500 MHz, CDCl3) δ 3.67 (d, J 
= 5.3 Hz, 4H), 3.60 (d, J = 11.8 Hz, 2H), 1.44 (s, 3H), 1.40 (s, 3H), 0.83 (s, 3H).  
  
(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl 4-methylbenzenesulfonate (5)  
This procedure was adapted from previously reported procedures.2 Compound (4) (10.89 g, 68.0 
mmol) was dissolved in 34 ml of pyridine and it was added dropwise to the stirred solution of p-
toluenesulfonyl chloride (35.70 g, 0.187 mol) in 48 mL of pyridine at 0 oC under nitrogen. After 
the complete addition, reaction mixture was stirred 48 h at room temperature. Then the reaction 
mixture was added dropwise to 100 ml of 40% ammonium chloride solution at 0 oC. After 
complete addition, it was allowed to stir at room temperature for 2 h. Then it was filtered and 
washed with DI water until the pyridine smell was gone. Then the residue was dissolved in 25 ml 
of DCM and extracted with half saturated ammonium chloride and saturated NaCl solution. 
Yellow DCM solution was dried with anhydrous sodium sulfate. Then the solvent was evaporated, 
and the residue was placed under full vacuum for 12 h to give (5) as a yellow solid with 89% yield 
(19.02 g). 1H NMR (500 MHz, CDCl3) δ 7.86 – 7.79 (m, 2H), 7.38 (d, J = 7.6 Hz, 2H), 4.11 (s, 





5-(azidomethyl)-2,2,5-trimethyl-1,3-dioxane (6)  
This procedure was adapted from previously reported procedures.2 Compound 5 (14.60 g, 46.4 
mmol), NaN3 (12.07 g, 186 mmol), water (10 mL), and DMF (80 mL) were stirred at 110 °C for 
48 h under reflux. The mixture was poured into 150 ml water and extracted four times with Et2O 
(4 × 200 mL). The organic phase was dried over anhydrous MgSO4 and the solvent was removed 
under reduced pressure. The residue was purified by column chromatography with silica gel (100 
g) and ethyl acetate/n-hexane (1:4) to give 7.48 g of a colourless liquid with an 87% yield. 1H 
NMR (500 MHz, CDCl3) δ 3.58 (d, J = 2.8 Hz, 4H), 3.51 (s, 2H), 1.40 (d, J = 13.8 Hz, 6H), 0.81 
(d, J = 1.1 Hz, 3H).  
  
2-(azidomethyl)-2-methylpropane-1,3-diol (7)  
This procedure was adapted from previously reported procedures.4 Compound (6) (7.05 g, 40.2 
mmol) was dissolved in 35 ml of methanol. 7.00 g of a Dowex, H+ resin was added, and the 
reaction mixture was stirred for 12 h at 50 oC. When the reaction was complete the Dowex, H+ 
resin was filtered off in a vacuum filter under a low vacuum and carefully washed with methanol. 
The methanol was evaporated to give 5.41 g of white crystals with a 93% yield. 1H NMR (400 
MHz, CDCl3) δ 3.73 – 3.58 (m, 4H), 3.56 – 3.43 (m, 2H), 2.19 (s, 2H), 0.89 (d, J = 2.0 Hz, 3H).  
 
A-MPA-4-AC (8)  
This procedure was adapted from previously reported procedures.3 Compound 2 (6.48 g, 37.2 
mmol), 1,1'-carbonyldiimidazole (CDI) (9.05 g, 55.8 mmol) were dissolved in 30 ml of ethyl 
acetate and it was stirred 1 h at 50 °C. CsF (0.75 g, 4.93 mmol), Compound (7) (1.80 g, 12.4 mmol) 
were dissolved in 10 ml of ethyl acetate separately and it was slowly added to the reaction mixture 
under nitrogen at 50 oC. It was stirred 12 h. When the reaction was complete 200 ml DI water was 
added and allowed to stir 2 h at room temperature. Then it was extracted with 1 M HCl (200 ml x 
3), 1 M NaHSO4 (200 ml x 3), 10% Na2CO3, saturated NaCl (200 ml) and it was dried under 
anhydrous MgSO4. Ethyl acetate was evaporated to give 5.22 g of colourless oil liquid with a 92% 
yield. 1H NMR (500 MHz, CDCl3) δ 4.21 (d, J = 11.7 Hz, 4H), 4.13 – 4.09 (m, 4H), 3.68 (d, J = 
11.7 Hz, 4H), 3.42 – 3.39 (m, 2H), 1.43 (d, J = 32.2 Hz, 12H), 1.18 (d, J = 1.6 Hz, 6H), 1.08 (d, J 
= 1.5 Hz, 3H).  
 
A-MPA-4-OH (9)  
This procedure was adapted from previously reported procedures.4 Compound (8) (5.00 g, 10.9 
mmol) was dissolved in 20 ml of methanol. 5.00 g of a Dowex, H+ resin was added, and the 
reaction mixture was stirred for 12 h at 50 oC. When the reaction was complete the Dowex, H+ 
resin was filtered off in a vacuum filter under a low vacuum and carefully washed with methanol. 
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The methanol was evaporated to give 3.96 g of colourless liquid with a 96% yield. 1H NMR (300 
MHz, CDCl3) δ 4.09 (s, 4H), 3.88 (d, J = 11.2 Hz, 4H), 3.78 – 3.67 (m, 4H), 3.43 (s, 4H), 3.38 (s, 
2H), 1.12 – 1.09 (m, 6H), 1.09 – 1.07 (m, 3H).  
 
A-MPA-4-FA (10)  
This procedure was adapted from previously reported procedures.1 To the stirred solution of (9) 
(3.25 g, 8.61 mmol), TEA (13.94 g, 138 mmol), 4-dimethylaminopyridine (DMAP) (3.15 g, 25.8 
mmol) in 50 ml DCM at 0 oC under nitrogen, palmitoyl chloride (18.93 g, 68.9 mmol) was 
dissolved in 20 ml DCM and it was added dropwise. After the complete addition, it was stirred 12 
h at room temperature. 150 ml of DI water was added, and it was stirred 1 h. Then the DCM layer 
was separated, and it was dried under anhydrous MgSO4. DCM was evaporated to give yellow 
residue further purified by the Sephadex-LH-20 column in DCM to give 10.86 g of yellow solid 
with a 91% yield. 1H NMR (300 MHz, CDCl3) δ 4.22 (d, J = 1.5 Hz, 8H), 4.01 (s, 4H), 3.32 (s, 
2H), 2.30 (t, J = 7.5 Hz, 8H), 1.59 (t, J = 7.4 Hz, 8H), 1.31 (d, J = 5.8 Hz, 104H), 1.04 – 0.99 (m, 
3H), 0.91 – 0.86 (m, 18H).  
 
((tetrahydro-2H-pyran-2-yl)oxy)methanamine (11)   
This procedure was adapted from previously reported procedures.5 To the stirred solution of 2-
Benzylaminoethanol (5.0 g, 33.1 mmol) in 17 mL of DCM at 0 oC, methanesulfonic acid (3.50 g, 
36.4 mmol) was added at 15 oC. After 45 min 3,4-dihydro-2H-pyran (4.73 g, 56.2 mmol) was 
added at 10-15 oC. It was stirred for 1 h at 15 oC. Upon 1H NMR confirmation of completion, 3 N 
caustic solution (17 mL, 49.1 mmol) was added at 5-10 oC. The phases were separated, and the 
organic layer was concentrated in the vacuum line. The oily yellow crude product was purified by 
short path distillation at 3 x 103 mbar and 117-125 oC. 1.0 g of crude product was dissolved in 15 
mL of ethanol and Pd/C (5 wt%, 327 mg, 0.154 mmol) was added at room temperature overnight 
under hydrogen balloon. Upon 1H NMR confirmation of completion, the reaction mixture was 
filtered through a celite pad. Then the filtrate was concentrated in vacuum to give 0.53 g of 
compound 11 with 86 % yield.  1H NMR (500 MHz, CDCl3) δ 4.66 – 4.58 (m, 1H), 3.94 – 3.75 
(m, 2H), 3.64 (dt, J = 16.4, 5.9 Hz, 1H), 3.58 – 3.40 (m, 2H), 2.90 (q, J = 11.8, 8.7 Hz, 2H), 1.89 
– 1.69 (m, 2H), 1.61 – 1.56 (m, 4H).  
 
P-PAMAM-G-0.5 (12)  
To the stirred solution of propargyl amine (5.10 g, 0.0800 mmol) in 50 mL of methanol, methyl 
acrylate (MA) (35.38 g, 0.410 mmol) in 150 mL of methanol was added dropwise under-salted 
ice. After the completion of the addition, the reaction mixture was allowed to come to room 
temperature and then was subjected to heating at 35 oC overnight. Upon 1H NMR confirmation of 
completion, MA was co-evaporated in-vacuo three times with butanol, three washes with reagent 
alcohol, and three with MeOH until complete removal was confirmed by 1H NMR in CDCl3 with 
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97% yield. 1H NMR (500 MHz, Chloroform-d) δ 3.65 (d, J = 3.5 Hz, 6H), 2.82 (q, J = 7.0, 5.3 Hz, 
4H), 2.45 (q, J = 7.0, 5.2 Hz, 4H), 2.19 (t, J = 2.9 Hz, 1H).  
 
P-PAMAM-G-1.0 (13)  
To the stirred solution of ethylenediamine (EDA) (52.1 g, 0.866 mmol) in 100 mL of methanol, 
12 (5.09 g, 0.0220 mmol) in 50 mL of methanol was added dropwise under-salted ice. After the 
completion of the addition, the reaction mixture was allowed to come to room temperature and 
then was subjected to heating at 35 oC overnight. Upon 1H NMR confirmation of completion, MA 
was co-evaporated in-vacuo three times each with butanol, reagent alcohol, and MeOH until 
complete removal was confirmed by 1H NMR in MeOD with 90% yield. 1H NMR (500 MHz, 
MeOD) δ 3.58 (t, J = 6.5 Hz, 5H), 3.53 – 3.47 (m, 2H), 3.28 (t, J = 6.2 Hz, 4H), 2.86 (t, J = 6.7 Hz, 
5H), 2.75 (t, J = 6.2 Hz, 5H), 2.65 (t, J = 2.6 Hz, 1H), 2.41 (t, J = 6.7 Hz, 4H), 2.20 (t, J = 2.9 Hz, 
1H).  
 
P-PAMAM-G-1.5 (14)  
To the stirred solution of MA (53.30 g, 0.620 mmol) in 200 mL of methanol, 13 (5.94 g, 0.0620 
mmol) in 50 mL in methanol was added dropwise under-salted ice. After the completion of the 
addition, the reaction mixture was allowed to come to room temperature and then was subjected 
to heating at 35 oC for two days. Upon 1H NMR confirmation of completion, MA was co-
evaporated in-vacuo three times with butanol, three with reagent alcohol, and three with MeOH 
until complete removal was confirmed by 1H NMR in CDCl3 with 95% yield. 
1H NMR (500 MHz, 
CDCl3) δ 3.70 (d, J = 1.5 Hz, 13H), 3.49 (d, J = 2.2 Hz, 2H), 3.32 (q, J = 5.8 Hz, 4H), 2.88 (t, J = 
6.7 Hz, 4H), 2.79 (t, J = 6.6 Hz, 9H), 2.57 (t, J = 6.0 Hz, 3H), 2.46 (t, J = 6.7 Hz, 9H), 2.41 (t, J = 
6.8 Hz, 4H), 2.19 (t, J = 2.9 Hz, 1H).  
 
P-PAMAM-G-2.0 (15)  
To the stirred solution of EDA (47.56 g, 793 mmol) in 100 mL of methanol, 14 (12.51g, 9.87 
mmol) in 60 mL in methanol was added dropwise under-salted ice. After the completion of the 
addition, the reaction mixture was allowed to come to room temperature and then it was subjected 
to heating at 35 oC for three days. Upon 1H NMR confirmation of completion, MA was co-
evaporated in-vacuo three times with butanol, three with reagent alcohol, and three with MeOH 
until complete removal was confirmed by 1H NMR in MeOD with 91% yield. 1H NMR (500 MHz, 
CDCl3) δ 3.56 (t, J = 6.7 Hz, 12H), 3.39 (t, J = 4.7 Hz, 2H), 3.21 (m, J = 12.0, 6.0 Hz, 8H), 2.76 
(t, J = 5.9 Hz, 8H), 2.69 (dd, J = 11.0, 4.7 Hz, 8H), 2.47 (t, J = 6.2 Hz, 2H), 2.29 (d, J = 21.8 Hz, 
18H), 2.20 (t, J = 2.9 Hz, 1H).  
 
P-PAMAM-G-2.5 (16)  
To the stirred solution of MA (71.84 g, 834 mmol) in 150 mL of methanol, 15 (12.45 g, 16.7 
mmol) in 60 mL in methanol was added dropwise under-salted ice. After the completion of the 
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addition, the reaction mixture was allowed to come to room temperature and then it was subjected 
to heating at 35 oC for four days. Upon 1H NMR confirmation of completion, MA was co-
evaporated in-vacuo three times with butanol, three with reagent alcohol, and three with MeOH 
until complete removal was confirmed by 1H NMR in CDCl3 with 94% yield. 
1H NMR (300 MHz, 
CDCl3) δ 3.68 (s, 24H), 3.47 (s, 2H), 3.30 (d, J = 5.8 Hz, 12H), 2.79 (dt, J = 13.6, 6.5 Hz, 28H), 
2.57 (dt, J = 12.2, 6.0 Hz, 12H), 2.44 (t, J = 6.7 Hz, 16H), 2.38 (t, J = 6.3 Hz, 12H), 2.19 (t, J = 2.9 
Hz, 1H).  
 
P-PAMAM-G-3.0 (17)  
To the stirred solution of EDA (34.31 g, 571 mmol) in 70 mL of methanol, 16 (10.24 g, 7.14 mmol) 
in 50 mL in methanol was added dropwise under-salted ice. After the completion of the addition, 
the reaction mixture was allowed to come to room temperature and then it was subjected to heating 
at 35 oC for four days. Upon 1H NMR confirmation of completion, MA was co-evaporated in-
vacuo three times with butanol, three with reagent alcohol, and three with MeOH until complete 
removal was confirmed by 1H NMR in MeOD with an 88% yield. 1H NMR (500 MHz, MeOD) δ 
3.57 (t, J = 6.7 Hz, 4H), 3.39 – 3.34 (m, 16H), 3.32 – 3.26 (m, 28H), 2.81 (tq, J = 12.8, 6.4 Hz, 
48H), 2.61 (q, J = 6.8 Hz, 14H), 2.39 (t, J = 7.0 Hz, 30H).  
 
P-PAMAM-TBE (18)  
To the stirred solution of 15 (22.00 g, 29.7 mmol) in 110 mL of methanol, tertbutyl acrylate (TBA) 
(190.53 g, 149 mmol) in 380 mL methanol was added dropwise under-salted ice. After the 
complete addition of TBA, the reaction was allowed to warm to room temperature. The reaction 
continued at room temperature for two days. Upon 1H NMR confirmation of completion, a single 
rotovap ensued. The PAMAM product was dissolved into a minimal amount of DCM which was 
followed by precipitation via separatory funnel into 5x mL of stirring, pure hexane. After settling, 
the hexane layer was decanted, and the remaining product was air-dried. This precipitation, 
decanting, and the air-drying process was repeated twice more. A final 1H NMR ensured the 
removal of TBA with 90% yield. 1H NMR (500 MHz, CDCl3) δ 3.47 (s, 2H), 3.35 (s, 18H), 3.26 
(s, 26H), 2.74 (s, 24H), 2.56 (d, J = 15.4 Hz, 14H), 2.37 (s, 28H), 2.19 (t, J = 2.9 Hz, 1H), 1.45 (s, 
72H).  
  
P-PAMAM-BOC (19)  
To the stirred solution of 17 (15.06 g, 9.04 mmol) in 150 mL of methanol, di-tert-butyl dicarbonate 
(Boc Anhydride) (39.85 g, 0.182 mmol) in 120 mL in methanol was added dropwise under-salted 
ice. After the complete addition of Boc Anhydride, the reaction was allowed to warm to room 
temperature. The reaction continued at room temperature for two days. Upon 1H NMR 
confirmation of completion, a single rotovap ensued. The PAMAM product was dissolved into a 
minimal amount of DCM which was followed by precipitation via separatory funnel into 5x mL 
of stirring, pure hexane. After settling, the hexane layer was decanted, and the remaining product 
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was air-dried. This precipitation, decanting, and the air-drying process was repeated twice more. 
A final 1H NMR ensured the removal of Boc Anhydride with a 92% yield. 1H NMR (400 MHz, 
CDCl3) δ 3.62 (s, 2H), 3.32 (q, J = 5.6 Hz, 18H), 3.24 (t, J = 6.2 Hz, 28H), 2.80 – 2.65 (m, 28H), 
2.53 (q, J = 7.9, 6.0 Hz, 14H), 2.36 (q, J = 9.0, 6.7 Hz, 28H), 2.23 (s, 1H), 1.42 (s, 72H).  
  
P-PAMAM-THP (20)  
To the stirred solution of 16 (15.06 g, 9.04 mmol) in 150 mL of methanol, ((tetrahydro-2H-pyran-
2-yl)oxy)methanamine (THP) (11)  (39.85 g, 0.182 mmol) in 120 mL in methanol was added 
dropwise under-salted ice. After the complete addition of THP, the reaction was allowed to warm 
to room temperature. The reaction continued at room temperature for four days. Upon 1H NMR 
confirmation of completion, a single rotovap ensued. The PAMAM product was dissolved into a 
minimal amount of DCM which was followed by precipitation via separatory funnel into 5x mL 
of stirring, pure hexane. After settling, the hexane layer was decanted, and the remaining product 
was air-dried. This precipitation, decanting, and the air-drying process was repeated twice more. 
It was further purified using size exclusion chromatography (Sephadex LH-20). A final 1H NMR 
ensured the removal of excess THP with 81% yield. 1H NMR (500 MHz, CDCl3) δ 4.57 (s, 8H), 
3.94 – 3.72 (m, 18H), 3.48 (d, J = 31.1 Hz, 28H), 3.34 (s, 12H), 2.97 – 2.61 (m, 24H), 2.36 (s, 
16H), 1.81 (s, 52H), 1.63 – 1.36 (m, 48H).  
 
Reported below are the full synthetic details for the preparation of macromolecules  
 
FA-PAMAM-NH3
+   
 
To the stirred solution of P-PAMAM-Boc (3.20 g, 1.31 mmol), A-MPA-4-FA (2.72 g, 1.957 
mmol) in 25 ml of DMF, CuBr (374.0 mg, 2.61 mmol) was added under nitrogen flushing. After 
complete addition, N,N,N′,N′′,N′′-Pentamethyldiethylenetriamine (PMDETA) (452.2 mg, 2.61 
mmol) was added and allowed to stir under nitrogen at 35 oC for 48 h. The reaction mixture was 
precipitated to 200 ml diethyl ether. After settling, the diethyl ether layer was decanted, and the 
remaining product was air-dried. This precipitation, decanting, and the air-drying process was 
repeated twice more. The crude product was dissolved in 100 ml of DCM. It was extracted with 
0.1 M EDTA solution. It was further purified using size exclusion chromatography (Sephadex LH-
20) to give 3.95 g of FA-PAMAM-BOC. It was dissolved in 45 ml of chloroform and 4.5 mL (10% 
v/v) of trifluoroacetic acid (TFA) was slowly added and stirred for 45 minutes. The reaction 
mixture was air-dried and dissolved in 10 mL of chloroform. It was added dropwise to 500 mL of 
diethyl ether and stirred for 2 h. It was filtered and precipitation procedure was repeated three 
times. Finally, the resulting yellow solid was put under the vacuum for 24 hours to obtain the pure 
product with 86% yield. 1H NMR for FA-PAMAM-Boc (500 MHz, CDCl3) δ 7.87 (s, 1H), 5.87-
5.70 (m, 8H), 4.40 (s, 2H), 4.29 (s, 2H), 4.26 (s, 4H), 4.23 (s, 8H), 3.31 (m, 28H), 3.23 (m, 18H), 
2.81 (m, 28H), 2.49 (m, 14H), 2.29 (q, 28H) ,1.42 (s, 72H), 1.30-1.22 (m, 104H), 1.01 (s, 3H), 
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0.98 (s, 6H), 0.86 (t, 12H). 13C NMR (101 MHz, Chloroform-d) δ 172.99, 172.07, 156.40, 144.29, 
125.79, 78.99, 77.40, 64.87, 52.45, 47.84, 44.21, 33.97, 31.81, 29.58, 24.80, 22.56, 17.73, 13.95.  
  
FA-PAMAM-COOH   
 
To the stirred solution of P-PAMAM-TBE (2.50 g, 1.32 mmol), A-MPA-4-FA (1.67 g, 1.29 mmol) 
in 25 ml of DMF, CuBr (374.0 mg, 2.61 mmol) was added under nitrogen flushing. After complete 
addition, PMDETA (452.2 mg, 2.61 mmol) was added and allowed to stir under nitrogen at 35 oC 
for 48 h. The reaction mixture was precipitated to 200 ml diethyl ether. After settling, the diethyl 
ether layer was decanted, and the remaining product was air-dried. This precipitation, decanting, 
and the air-drying process was repeated twice more. The crude product was dissolved in 100 ml 
of DCM. It was extracted with 0.1 M EDTA solution. It was further purified using size exclusion 
chromatography (Sephadex LH-20) to give FA-PAMAM-TBE as a yellow solid. Then 2 g of FA-
PAMAM-TBE was dissolved in 30 ml of chloroform and 3.0 mL (10% v/v) of TFA was added 
dropwise and stirred for 45 minutes. The reaction mixture was air-dried and dissolved in 8 mL of 
chloroform. It was added dropwise to 500 mL of diethyl ether and stirred for 2 h. It was filtered 
and precipitation procedure was repeated three times. Finally, the resulting yellow solid was put 
under the vacuum for 24 h to obtain the pure product with 82% yield. 1H NMR for FA-PAMAM-
TBE (400 MHz, CDCl3) δ 7.82 (s, 1H), 5.91-5.60 (m, 4H), 4.39 (s, 2H), 4.29 (s, 2H), 4.26 (s, 4H), 
4.22 (s, 8H), 4.01 (s, 8H), 3.32 (m, 18H), 3.22 (m, 26H), 2.84 (s, 24H), 2.47 (s, 28H), 2.30 (t, 14H), 
1.42 (s, 72H), 1.27 – 1.24 (m, 104H), 1.01 (s, 3H), 0.98 (s, 6H), 0.89 – 0.87 (m, 14H).13C NMR 
(126 MHz, CDCl3) δ 173.13, 171.92, 162.49, 142.91, 125.24, 66.00, 64.86, 52.81, 52.49, 51.60, 
49.19, 46.47, 37.16, 36.42, 34.60, 29.65, 25.21, 24.81, 17.82, 14.05.  
  
FA-PAMAM-OH   
 
To the stirred solution of P-PAMAM-THP (1.04 g, 0.428 mmol), A-MPA-4-FA (0.86 g, 0.642 
mmol) in 10 ml of DMF, CuBr (130.0 mg, 0.856 mmol) was added under nitrogen flushing. After 
complete addition, PMDETA (149.4 mg, 0.856 mmol) was added and allowed to stir under 
nitrogen at 35 oC for 48 h. The reaction mixture was precipitated to 200 ml diethyl ether. After 
settling, the diethyl ether layer was decanted, and the remaining product was air-dried. This 
precipitation, decanting, and the air-drying process was repeated twice more. The crude product 
was dissolved in 100 ml of DCM. It was extracted with 0.1 M EDTA solution. It was further 
purified using size exclusion chromatography (Sephadex LH-20) to give 1.27 g of a solid. Then 
1g of FA-PAMAM-THP was dissolved in 15 ml of chloroform and 2.0 mL of TFA was added 
dropwise and stirred for 60 minutes. The reaction mixture was air-dried and dissolved in 5 mL of 
chloroform. It was added dropwise to 250 mL of diethyl ether:methanol mixture (2:1) and stirred 
for 2 h. It was filtered and precipitation procedure was repeated three times. Finally, the resulting 
yellow solid was put under the vacuum for 24 h to obtain the pure product with a 79 % yield. 1H 
33 
NMR for FA-PAMAM-THP (400 MHz, CDCl3) δ 7.89 (s, 1H), 4.60 (s, 8H), 4.25 (s, 8H), 3.89 (s, 
28H), 3.55 (s, 18H), 2.32 (s, 12H), 1.36 – 1.23 (m, 104H), 0.91 (s, 18H). 13C NMR (101 MHz, 
Chloroform-d) δ 174.10, 172.96, 162.45, 142.04, 125.99, 98.88, 77.32, 66.30, 65.08, 63.76, 54.91, 
46.50, 39.57, 34.05, 31.95, , 29.72, 25.47, 22.73, 22.71, 19.69, 17.87, 13.96. 
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 NMR SPECTRA 
   










   
Figure S3. 1H NMR for (2,2,5-trimethyl-1,3-dioxan-5-yl)methyl 4-methylbenzenesulfonate (5) 
(500 MHz, CDCl3)  
 
  




Figure S5. 1H NMR for 2-(azidomethyl)-2-methylpropane-1,3-diol (7) (400 MHz, CDCl3)  
 
  













Figure S9. FTIR spectra for A-MPA-4-FA (10) 
  







Figure S11. 1H NMR for P-PAMAM-G0.5 (500 MHz, CDCl3)   
 
   



















Figure S15. 1H NMR for P-PAMAM-G2.5 (500 MHz, CDCl3)   
 
   




Figure S17. 1H NMR for P-PAMAM-BOC (400 MHz, CDCl3)  
 
  
Figure S18. 1H NMR for P-PAMAM-G-3.0-THP (500 MHz, CDCl3)  
43 
  
Figure S19. 1H NMR comparison for FA-PAMAM-TBE with P-PAMAM-TBE and A-MPA-4-
FA (500 MHz, CDCl3)  




Figure S21. 13C NMR for FA-PAMAM-TBE (300 MHz, CDCl3)  
 
  
   




Figure S23. 1H NMR comparison for FA-PAMAM-BOC with P-PAMAM-BOC and A-MPA-4-
FA (500 MHz, CDCl3)  
  
Figure S24. 1H NMR for FA-PAMAM-BOC (500 MHz, CDCl3)  
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Figure S25. 13C NMR for FA-PAMAM-BOC (400 MHz, CDCl3)  
  
  
Figure S26. 1H NMR comparison for (a) FA-PAMAM-BOC, (b) FA-PAMAM-NH3





Figure S27. 1H NMR comparison for FA-PAMAM-THP with P-PAMAM-THP and A-MPA-4-



















Figure S31. GPC chromatograms for 4-FA-PAMAM-BOC in THF 
 
Figure S32. GPC chromatograms for 4-FA-PAMAM-TBE in THF 
 





Figure S31. DLS spectra for FA-PAMAM-G3-NH3
+, left: Size distribution by number, right: Size 
distribution by intensity 
 
 
Figure S32. DLS spectra for FA-PAMAM-G3-COO-, left: Size distribution by number, right: Size 
distribution by intensity 
 
 
Figure S33. DLS spectra for FA-PAMAM-G3-OH, left: Size distribution by number, right: Size 







Figure S34. Excitation ratio vs. log concentration for FA-PAMAM-G3-NH3
+ (left) and FA-
PAMAM-G3- COO- (right) 
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